论文部分内容阅读
目的由于在绝经过程至绝经后不同时期绝经HT的利益-危险比不同,北美绝经协会NAMS为临床医生和大众,于2007年3月发表了以循证医学为基础的,关于绝经后妇女应用HT的立场声明。设计征募专门从事妇女保健工作的有经验的临床医生与研究员组成专家组,再评议2007年3月的立场声明,以循证分析法评估现有证据,并在推荐意见上达成共识。专家组的推荐意见由NAMS理事会,按正式立场声明的标准,进行审评并批准。将该文件提供给其他感兴趣的组织机构,以寻求他们的赞同。结果鉴于对绝经前后HT潜在利益和危险的认识,现有证据支持关于HT在绝经后妇女中作用的共识。本文列出涉及到的领域及相关的解释和说明。强调了与2007年立场声明的不同之处。附录包含对“危险”概念的讨论,新增2007年声明中没有的内容,和对未来HT研究领域的建议。文中还列出主要的参考文献目录。结论现有数据支持在绝经前后启动HT治疗绝经相关症状;治疗某些疾病或降低其发生危险,例如,对于绝经后骨质疏松或骨折者,可有选择地进行预防或治疗。绝经HT的利益-危险比在绝经前后短期最优,在未治疗妇女中该利益-危险比随着年龄的增长以及绝经时间的延长而降低。
Purpose Because of the benefit-risk ratio of menopausal HT to menopausal HT at different periods after menopause, NAMS North American Association for Clinicians and Volkswagen published in March 2007 an evidence-based medicine on post-menopausal women using HT Position statement. Design an expert group of experienced clinicians and researchers specializing in women’s health care work, review the position statement of March 2007, evaluate the evidence available through evidence-based analysis, and agree on the recommendations. The panel’s recommendations are reviewed and approved by the NAMS Council on the basis of the formal position statement. The document is provided to other interested organizations to seek their approval. Results In light of the understanding of the potential benefits and risks of HT before and after menopause, available evidence supports consensus regarding the role of HT in postmenopausal women. This article lists the areas covered and related explanations and explanations. Highlighted the differences from the 2007 position statement. The appendix contains a discussion of the notion of “danger”, new additions to the 2007 statement, and recommendations for future HT research areas. The article also lists the main bibliography. CONCLUSIONS Current data support the initiation of HT for the treatment of menopausal symptoms before and after menopause; the treatment of certain diseases or the reduction of their risk; for example, prophylactic or therapeutic treatment for postmenopausal osteoporosis or fractures. The benefit of menopausal HT-hazard is best than short-term before and after menopause, which is reduced with age and prolonged menopause in untreated women.